High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor.
Delaidelli A, Burwag F, Ben-Neriah S, Suk Y, Shyp T, Kosteniuk S, Dunham C, Cheng S, Okonechnikov K, Schrimpf D, von Deimling A, Ellezam B, Perreault S, Singh S, Hawkins C, Kool M, Pfister SM, Steidl C, Hughes C, Korshunov A, Sorensen PH.
Delaidelli A, et al.
Neuro Oncol. 2025 Oct 14;27(9):2431-2444. doi: 10.1093/neuonc/noaf046.
Neuro Oncol. 2025.
PMID: 40040502